2026-01-22 - Analysis Report
## Financial Report for Align Technology (ALGN)
### Company Overview
Align Technology is a medical device company that specializes in the development and marketing of clear aligner therapy, a non-invasive and removable solution for teeth straightening.

### Performance Comparison
- **Rate (ALGN)**: -47.41%
- **Rate_vs (VOO)**: 91.55%
- **Divergence**: -140.20 (Relative divergence: 4.20%)
The divergence between Align Technology and S&P 500 shows a significant difference in return rates. The cumulative return for Align Technology is lower, while S&P 500 has a higher cumulative return.

### Alpha, Beta Analysis
|        | CAGR | MDD  | Alpha | Beta | Cap(B) |
|--------|------|------|-------|------|-------|
| 2016-2018| 47.0%| 48.8%| 42.0% | 1.5  | 15.2B |
| 2017-2019| 69.0%| 50.2%| 51.0% | 1.6  | 20.2B |
| 2018-2020| -23.0%| 50.2%| -44.0%| 1.5  | 38.7B |
| 2019-2021| 16.0%| 45.1%| -28.0%| 1.5  | 47.6B |
| 2020-2022| -108.0%| 75.2%| -106.0%| 1.5  | 15.3B |
| 2021-2023| -138.0%| 75.2%| -139.0%| 1.7  | 19.9B |
| 2022-2024| -79.0%| 64.3%| -99.0%| 1.7  | 15.1B |
| 2023-2025| -25.0%| 57.2%| -87.0%| 1.5  | 11.3B |

### Recent Stock Price Fluctuations
- **Close**: $169.95
- **Last-market**: {'price': 169.95, 'previousClose': 165.55, 'change': 2.66}
- **5-day SMA**: $169.54
- **20-day SMA**: $164.41
- **60-day SMA**: $152.06
The stock price has shown a sharp rebound in the last few days with the 5-day and 20-day SMA still below the current price.

### RSI, PPO Index Indicators and Delta_Previous_Relative_Divergence
- **MRI**: 0.80 (High Investment Recommended)
- **RSI**: 66.08
- **PPO**: -0.18
- **Expected Return**: -1656.90%
The MRI suggests a medium investment risk, but the high RSI value indicates that the stock is overbought, and the negative PPO value suggests a bearish trend.

### Recent News & Significant Events
1. [2026-01-21] Align Tech (ALGN) Receives a Hold from UBS - The Globe and Mail
2. [2026-01-17] Assessing Align Technology (ALGN) Valuation After Recent Share Price Rebound And Modest Discount Signals - simplywall.st
3. [2026-01-14] 3 Reasons to Avoid ALGN and 1 Stock to Buy Instead - Yahoo Finance
4. [2026-01-20] Mizuho Maintains "Outperform" Rating for ALGN, Raises Price Target - GuruFocus
5. [2025-10-30] Why Align Technology Stock Popped Today - The Motley Fool
6. [2025-10-30] Align Technology Stock Forecast: Where Analysts See the Stock by 2027 - TIKR.com

### Analyst Opinions
Analyst Consensus:
- **Key**: Buy
- **Mean (1=StrongBuy~5=Sell)**: 2.17 (~Buy)
- **Opinions**: 15
- **Target Price (avg/high/low)**: 182.47 / 220.00 / 150.00

### Recent Earnings Analysis
| Date | EPS | Revenue |
|------|----:|--------:|
| 2025-11-05 | 0.78 | 1.00 B$ |
| 2025-08-06 | 1.72 | 1.01 B$ |
| 2025-05-08 | 1.27 | 0.98 B$ |
| 2024-11-05 | 1.55 | 0.98 B$ |
| 2025-11-05 | 1.55 | 0.98 B$ |

The quarterly EPS shows a decline from 1.72 in 2025-08-06 to 0.78 in 2025-11-05, and the revenue has been relatively stable around 1.00 B$.

### Financial Information - Revenue and Profitability
| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $1.00B | 64.20% |
| 2025-06-30 | $1.01B | 69.94% |
| 2025-03-31 | $0.98B | 69.45% |
| 2024-12-31 | $1.00B | 70.03% |
| 2024-09-30 | $0.98B | 69.72% |

The revenue has been relatively stable, but the profit margin has shown fluctuations between 64.20% and 70.03%.

### Financial Information - Capital and Profitability
| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $3.96B | 1.43% |
| 2025-06-30 | $3.91B | 3.18% |
| 2025-03-31 | $3.79B | 2.46% |
| 2024-12-31 | $3.85B | 2.69% |
| 2024-09-30 | $3.94B | 2.94% |

The equity has shown fluctuations, but the ROE has been relatively stable around 2-3%.

### Comprehensive Analysis (Summary of previous items)
Align Technology has shown a significant decline in stock price with a cumulative return of -47.41%. The divergence between Align Technology and S&P 500 is -140.20. The company has shown fluctuations in profit margin and ROE. Analytical indicators suggest a bearish trend with a high RSI value and negative PPO value. Recent news and analyst opinions suggest a Buy recommendation with a target price of 182.47.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.